Abstract
The regulation of the immune system at the cell surface is primarily controlled by two families of cosignaling molecules: the immunoglobulin (Ig) superfamily, or CD28 and B7 family, and the tumor necrosis factor receptor (TNFR) family. Here, we summarized the principal structural and functional characteristics of both families. In this respect, the interaction between HVEM, a TNF receptor, and BTLA, an Ig family member, has provided a new perspective and an additional level of complexity in the crosstalk between these two regulatory systems. This review will present a summary of the recent advances in the immunobiology of the LIGHT-HVEM-LTβR-BTLA network. The LIGHT-HVEM-BTLA system has emerged as a major regulator of immune responses and lymphocyte activation, whereas LIGHT-LTβR participates in lymphoid tissue development and cell death. Moreover, recent studies have provided encouraging new insights into the roles of the LIGHT-HVEM-LTβR-BTLA axis as a potential target for controlling anti-tumor responses.
Current Molecular Medicine
Title: Cosignaling Molecules Around LIGHT-HVEM-BTLA: From Immune Activation to Therapeutic Targeting
Volume: 9 Issue: 7
Author(s): Christine Pasero, Alemseged Truneh and Daniel Olive
Affiliation:
Abstract: The regulation of the immune system at the cell surface is primarily controlled by two families of cosignaling molecules: the immunoglobulin (Ig) superfamily, or CD28 and B7 family, and the tumor necrosis factor receptor (TNFR) family. Here, we summarized the principal structural and functional characteristics of both families. In this respect, the interaction between HVEM, a TNF receptor, and BTLA, an Ig family member, has provided a new perspective and an additional level of complexity in the crosstalk between these two regulatory systems. This review will present a summary of the recent advances in the immunobiology of the LIGHT-HVEM-LTβR-BTLA network. The LIGHT-HVEM-BTLA system has emerged as a major regulator of immune responses and lymphocyte activation, whereas LIGHT-LTβR participates in lymphoid tissue development and cell death. Moreover, recent studies have provided encouraging new insights into the roles of the LIGHT-HVEM-LTβR-BTLA axis as a potential target for controlling anti-tumor responses.
Export Options
About this article
Cite this article as:
Pasero Christine, Truneh Alemseged and Olive Daniel, Cosignaling Molecules Around LIGHT-HVEM-BTLA: From Immune Activation to Therapeutic Targeting, Current Molecular Medicine 2009; 9 (7) . https://dx.doi.org/10.2174/156652409789105589
DOI https://dx.doi.org/10.2174/156652409789105589 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cardioprotection by Targeting the Pool of Resident and Extracardiac Progenitors
Current Drug Targets Human Embryonic and Induced Pluripotent Stem Cell Based Toxicity Testing Models: Future Applications in New Drug Discovery
Current Medicinal Chemistry Cardiac and Vascular Impairment in Patients with Mild Psoriasis: A Longitudinal Study
Current Vascular Pharmacology Re-Wiring the Circuit: Mitochondria as a Pharmacological Target in Liver Disease
Current Medicinal Chemistry Mitochondrial Diseases in Childhood
Current Molecular Medicine Current Nervous System Related Drug Targets for the Treatment of Amyotrophic Lateral Sclerosis
Current Pharmaceutical Design Genetic Privacy in Sports: Clearing the Hurdles
Recent Patents on DNA & Gene Sequences Hypertension in Type 2 Diabetes Mellitus: Do We Need to Redefine the Role of Sulfonylureas?
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Myocardial Inflammation in Autoimmune Diseases: Investigation by Cardiovascular Magnetic Resonance and Endomyocardial Biopsy
Inflammation & Allergy - Drug Targets (Discontinued) Fatty Liver and Ischemia/Reperfusion: Are there Drugs Able to Mitigate Injury?
Current Medicinal Chemistry The Role of Negative Costimulators During Parasitic Infections
Endocrine, Metabolic & Immune Disorders - Drug Targets The Mechanism of Dead-in-Bed Syndrome and Other Sudden Unexplained Nocturnal Deaths
Current Diabetes Reviews Inflammatory Markers in Coronary Artery Disease: Pathophysiological Mechanisms, Prognostic and Therapeutic Implications
Current Cardiology Reviews Markers of Arrhythmogenic Risk in Hypertensive Subjects
Current Pharmaceutical Design Radionuclide Imaging in Patients with Ischemic Heart Failure
Current Medical Imaging Cardioprotective Effects of Natural Products <i>via</i> the Nrf2 Signaling Pathway
Current Vascular Pharmacology The Failing Heart in Pediatric Dilated Cardiomyopathy Caused by Excessive Water Drinking: A Case Report and Brief Review
New Emirates Medical Journal Molecular Genetics of Early- and Late-Onset Alzheimer’s Disease
Current Gene Therapy Challenges in Treatment of Inappropriate Sinus Tachycardia
Current Cardiology Reviews Cardiac Workup of Ischemic Stroke
Current Cardiology Reviews